Myricetin ameliorates atherosclerosis in the low-density-lipoprotein receptor knockout mice by suppression of cholesterol accumulation in macrophage foam cells

Zhe Meng†, Mengyu Wang†, Junhui Xing, Yuzhou Liu and Haiyu Li*

Abstract

Background: Myricetin, a major flavonoid found in several foods including berries, grapes and wine, exhibited strong antioxidant potency, yet the effect on atherosclerosis is not fully understood. In this study, we examined the effect of myricetin on lipid accumulation in macrophage and atherosclerosis in atherosclerosis-prone low density lipoprotein receptor-deficient (Ldlr−/−) mice.

Methods: Ldlr−/− mice were fed an atherogenic diet supplemented with myricetin (0.15% in the diet, v/v) for 8 weeks. Body weight, adipose tissue weight, food intake, serum biochemical parameters were measured. Atherosclerosis lesions and macrophages accumulation in lesions were analyzed and quantified. Macrophages were exposed to 20 μM of myricetin before incubated with oxidized low-density lipoprotein (ox-LDL) (25μg/mL) or Dil-ox-LDL for the indicated time. Lipid uptake and foam cell formation were evaluated by flow cytometry and microscopy. The intracellular lipids were extracted and measured. mRNA expression and protein of cholesterol metabolism related receptors were analyzed.

Results: Myricetin administration reduced the weight, plasma lipid levels but not food intake in Ldlr−/− mice when fed an atherogenic diet. Myricetin-treated Ldlr−/− mice displayed significantly less atherosclerotic areas and macrophages in the cross sections of the aortic root. There were also less lipophilic areas in En face Oil red O staining of aorta from myricetin-treated Ldlr−/− mice. Myricetin treatment also markedly ameliorated ox-LDL-induced cholesterol accumulation in macrophages. The expression of CD36 were decreased in myricetin treated macrophages with ox-LDL incubation, while scavenger receptors class A (SR-A) and scavenger receptors class B (SR-BI) expression was not altered, indicating that these effect of myricetin were dependent on CD36 pathway.

Conclusions: Our findings indicated that myricetin suppressed cholesterol accumulation in macrophage foam cells by inhibition of CD36-mediated ox-LDL uptake, and suggested myricetin may have an important therapeutic function for atherosclerosis.

Keywords: Myricetin, Macrophage, Atherosclerosis, CD36
**Background**

Atherosclerosis, a leading cause of death worldwide, is characterized by excessive cholesterol deposition within the artery wall resulting in myocardial infarction and stroke [1, 2]. Atherosclerosis is a chronic inflammatory disorder of the vascular wall involving many circulating immune cells, such as monocytes, lymphocytes, and platelets [3]. Particularly, infiltration of monocytes and their subsequent formation of macrophage-derived foam cells and proinflammatory cytokine secretion is a crucial step in the progression of atherosclerosis [4, 5]. Modified LDL such as ox-LDL causes excessive cholesterol deposition in macrophages and leads to the formation of foam cells that play a crucial role in the initiation and progression of atherosclerosis [6, 7].

Myricetin is a naturally flavonoid extracted from wine, berries, grapes, vegetables and medicinal herbs. Flavonoids exhibited anti-inflammatory activity and had been reported as potent natural antioxidants that protect against modified LDL uptake in macrophages and attenuated the development of atherosclerosis [8, 9]. The beneficial effect of red wine consumption against the development of atherosclerosis may help to explain the ‘French Paradox’—a low incidence of cardiovascular events in southern France despite a diet rich in saturated fat [10, 11]. Myricetin has been shown to possess anti-inflammatory and antioxidant properties [12, 13]. Myricetin has also demonstrated the ability to anti-obesity, improve glucose utilization, modulate lipid metabolism [14–16]. It was reported that myricetin reduced the weight-gain, feed efficiency, level of blood lipids, adipocyte size, and weight and size of the perirenal and epididymal adipose tissues [16]. This anti-obesity effect may be involved in upregulation of adiponectin and β-endorphin levels. Furthermore, myricetin has been found to reduce hyperglycemia, ameliorating the impaired insulin-signaling pathway and improve glucose utilization in diabetes-like animal models [14, 17]. However, the effect of myricetin on the lipid metabolism and atherosclerosis is not fully understood.

We explored the interaction between myricetin effects and atherosclerosis used atherosclerosis-prone Ldlr<sup>−/−</sup> mice. Ldlr<sup>−/−</sup> mice fed an atherogenic diet (AsD) displayed dislipidemia and accelerated atherosclerosis. This study investigated the effects of myricetin on lipid metabolism and atherosclerosis in AsD fed Ldlr<sup>−/−</sup> mice. In addition to its anti-obesity effect, myricetin has beneficial effects on dislipidemia and atherosclerosis. The possible mechanism by which myricetin ameliorating atherosclerosis may be involved in improved lipid metabolism and suppression of cholesterol accumulation in macrophages.

**Methods**

**Animals**

Ldlr<sup>−/−</sup> mice were purchased from Jackson Laboratories (Bar Harbor, ME). All experiments involving mice were approved by the Institutional Animal Care Research Advisory Committee of the National Institute of Biological Science (NIBS) and Animal Care Committee of Zhengzhou University. Ldlr<sup>−/−</sup> mice were divided into 2 groups: Control group (n = 10), Myr group (n = 10). Control group were given an AsD (20% fat and 0.5% cholesterol). Myr group were fed with AsD and supplemented with myricetin (0.15% in the diet, v/v). All mice were maintained on a 12:12-h light-dark cycle and have free access to water and food. Body weight and food intake were monitored throughout the experiments.

**Cell culture**

Peritoneal macrophages were isolated from WT mice 3 days after intraperitoneal injection with a 4% solution of thioglycollate media. Isolated peritoneal macrophages were cultured in DMEM supplemented with 10% fetal bovine serum. Peritoneal macrophages were plated on chamber slides in 12-well plates. Treatments including serum starvation (DMEM only), myricetin treatment (20 μmol L<sup>−1</sup>) or control vehicle (DMSO).

**Blood metabolite analysis**

Blood was obtained by retro-orbital bleeding. Plasma total cholesterol (TC), and triglyceride (TG) were determined by enzymatic methods (Sigma kits, USA).

**Atherosclerosis lesion analysis**

12-week-old Ldlr<sup>−/−</sup> mice were fed an AsD (20% fat and 0.5% cholesterol). The aorta and aortic sinus sections were prepared and stained as described [18]. The lesion area of each aorta and aortic sinus were analyzed by using Image J software. Sections of aortic sinus were subjected to immunohistochemical staining with MAC-2 antibody (Santa Cruz Biotechnology, Dallas, Texas) for macrophages.

**Lipid uptake assay**

For Dil-oxLDL uptake macrophages was serum-starved in DMEM for 24 h. Macrophages were treated with or without myricetin (20 μmol L<sup>−1</sup>) for 20 h, then 10 g/mL Dil-oxLDL at 4°C for 4 h. Cells were washed and lysates were analyzed by fluorometry (Molecular Devices, Downingtown, PA) with 514 nm excitation and 550 nm emission.

**Foam cell formation**

Macrophages were cultured on chamber slides. Cells were starved for 24 h and treated with myricetin (20 μmol L<sup>−1</sup>) for 12 h, then cells were incubated with
ox-LDL (25μg/mL) for another 12 h. Upon fixation with PFA (4%) cells were stained with Oil-red O and evaluated by microscopy. To evaluate cholesterol ester accumulation, cells were incubated with BODIPHY 493/503 (Invitrogen) for the indicated time and flow cytometric analysis was performed. After 24 h incubation with ox-LDL, cells were washed 3 times with PBS, and then free cholesterol (FC), cholesterol ester (CE) and triglyceride (TG) were determined using commercial kits from Applygen Technologies (Beijing, China).

Western blot analysis
For Western blotting, cells were lysed using RIPA buffer. Equal amounts of protein (30 μg) were loaded and separated by 8% SDS-PAGE. Separated proteins were electrophoretically transferred to a nitrocellulose membrane, blocked with 5% (w/v) skim milk solution for 1 h, and then incubated with primary antibodies to CD36 (Santa Cruz Biotechnology, Inc., CA, USA; Cat. No. sc-9154), SR-BI (Abcam, Inc.; Cat. No. ab-18,180) and GAPDH (Abcam, Inc.; Cat. No. ab-181,602), respectively, overnight at 4 °C. Blots were visualized by an ECL system (Pierce).

RNA isolation and quantitative real-time PCR
Total RNA was extracted using Trizol reagent (Invitrogen, USA) and first-strand cDNA was generated by using an RT kit (Invitrogen, USA). Amplifications were performed using an opticon continuous fluorescence detection system (MJ Research) with SYBR green fluorescence (Molecular Probes, Eugene, USA). All samples were quantitated by using the comparative CT method for relative quantitation of gene expression, normalized to GAPDH. The following primers were used: CD36 (Forward: 5'-GAC CAG CTG GAC AAC ATA CTG CTA-3'; Reverse: 5'-CCC AGA GCA AAA AGC GAC TC-3); MCP-1 (Forward: 5'-TCC CAA TGA GTA GGC CAA-3'; Reverse: 5'-AAG GCA TTA GAA ACA GTC TAA-3); IL-6 (Forward: 5'-AGG CTC CGA GAT GAA A-3'; Reverse: 5'-GAT AAG GCT TGG CAA CCC AAG-3); ABCA1 (Forward: 5'-AAC ACG TAC CTC CCA GAC ATG CTT-3'; Reverse: 5'-AGT CGT CCA TTG CCA CAG-3); SR-BI (Forward: 5'-GAC CAG CTG GAC AAC ATA CTG CTA-3'; Reverse: 5'-CCC AGA GCA AAA AGC GAC TC-3); GAPDH (Abcam, Inc.; Cat. No. SC-9154), SR-B1 (Abcam, Inc.; Cat. No. ab-181,602), respectively, overnight at 4 °C. Blots were visualized by an ECL system (Pierce).

Statistical analysis
All data are presented as means ± SD. SPSS 19.0 was used to perform statistical analysis of the data. The Shapiro-Wilk test was performed to determine the distribution of the variables and non-normal distributions were log-transformed before statistical analysis with an independent t-Test. Variables that were analyzed with Mann-Whitney U test. A value of P < 0.05 was considered statistically significant.

Results
Myricetin ameliorates metabolic abnormalities in low density lipoprotein receptor-deficient (Ldlr<sup>-/-</sup>) mice fed an atherogenic diet
As shown in Fig. 1a, the body weight of myricetin-treated mice was significantly lower than that of mice in the Control group (21.86 ± 0.90 g vs 25.22 ± 1.30 g, P < 0.05) after feed with AsD for 8 weeks. No significantly difference in the total food intake was observed between Control group and Myr group mice (P = 0.19, Fig. 1b). As shown in Fig. 1c, the subcutaneous white adipose tissue weight (WAT) of Myr group mice was 7.72 ± 0.30 mg, this value was lower than that of Control group, 11.81 ± 0.63 mg, P < 0.001. The inguinal WAT, retroperitoneal WAT, and mesenteric WAT weight of Myr group mice were 1.45 ± 0.07 mg, 2.32 ± 0.16 mg and 8.55 ± 0.38 mg, respectively. These values were lower than that of Control group, 2.29 ± 0.33 mg, 2.86 ± 0.33 mg and 10.63 ± 0.86 mg, respectively, P < 0.05.

Plasma lipid levels were then analyzed. As shown in Fig. 2, the AsD caused the elevation of plasma TC, TG concentrations in mice. The TG and TC levels in Myr group mice, 140.1 ± 18.46 mg/dL and 1052 ± 60.16 mg/dL, were significantly lower (P < 0.05) than those of the Control group mice, 196.3 ± 17.28 mg/dL, 1308 ± 68.63 mg/dL, respectively. Taken together, these results show that myricetin can reduce body weight and lipid accumulation without decreasing food intake in AsD fed Ldlr<sup>-/-</sup> mice.

Myricetin alleviates atherosclerosis and macrophage accumulation in atherosclerotic lesions
To investigate whether myricetin affects the formation of atherosclerotic lesions, Ldlr<sup>-/-</sup> mice were placed on AsD with or without myricetin administration for 8 weeks. After 8 weeks, most lesions developed in ascending aorta and aortic arch. We performed en face analysis of the aorta and the results showed Myr group mice developed less atherosclerotic lesions compared to Control mice, however, the difference did not reach statistical significance (Fig. 3a) (3.31 ± 0.67% vs 4.111 ± 0.75%, P = 0.44). Quantification of Oil red-stained cross sections of aortic roots showed reduced plaque size in Myr mice when compared with Control mice (Fig. 3b) (105.2 ± 7.77% × 10<sup>3</sup> μm<sup>2</sup> vs 158.8 ± 16.94 × 10<sup>3</sup> μm<sup>2</sup>, P < 0.05).
These results indicate that myricetin may have a protective role in atherosclerosis.

To evaluate whether myricetin affects macrophage accumulation in the atherosclerotic lesions, we performed immunohistochemical staining of the aortic root tissue sections with an antibody that recognizes murine macrophages, Mac-2. The Mac-2-positive areas were analyzed with NIH Image J. There were more Mac-2-positive cells in the aortic lesions of Control mice when compared with Myr mice (Fig. 4a and b). Mac-2 positive area:
32.67 ± 3.46% vs 21.22 ± 3.03%, P<0.05. However, there was little or no difference in the amount of smooth muscle cells and collagen content within plaque lesions (data not shown). Furthermore, the expression of pro-inflammatory mediators such as MCP-1 and IL-6 were also reduced in the aorta of Myr mice (Fig. 4d). The expression of IL-10 in Myr mice was not different compared with Control mice (Fig. 4d). These findings indicate that myricetin treatment is not only important in regulating plaque size, but also, in determining plaque composition and morphology, which may have potential impact on plaque stability.

**Myricetin regulates foam cell formation**

To evaluate whether myricetin has a functional role in regulating lipid uptake, we thus explored the effect of myricetin on ox-LDL-induced foam cell formation. Treatment with myricetin markedly decreased ox-LDL induced cholesterol accumulation in macrophages, as revealed by cellular cholesterol content and Oil-red O staining (Fig. 5a, b and e) (75.70 ± 5.43 μg/mg vs 94.74 ± 6.28 μg/mg, P<0.05). Therefore, myricetin may regulate cholesterol metabolism of macrophage foam cells.

Consistent with decreased foam cell formation, BODIPY fluorescence, which is a marker of cellular lipid droplets, was reduced in macrophages treated with myricetin (Fig. 5c). Furthermore, cholesterol ester content was decreased in macrophages upon treatment with ox-LDL as compared to vehicle macrophages (Fig. 5e) (7.288 ± 1.80 μg/mg vs 13.90 ± 2.23 μg/mg, P<0.05). However, Myricetin did not alter the intracellular triglyceride

---

**Fig. 3** Effect on atherosclerosis lesions. Representative en face images of oil red O-stained aorta and quantification of lesion area (a) and Representative aortic root sections stained with oil red O and quantification of aortic lesion areas (b). Values are expressed as mean ± SD. N = 10, *P < 0.05, for Myr mice vs. Control mice.
accumulation induced by ox-LDL (Fig. 5e) (59.03 ± 8.23 μg/mg vs 61.63 ± 11.57 μg/mg, \( P < 0.05 \)). Taken together, these findings suggest that myricetin plays a critical role in macrophage foam cell formation.

The mechanisms of reduced lipid accumulation in myricetin treated macrophages

To explore the mechanism underlying the protective effect of myricetin, we examined the expression of several key factors in atherogenesis in macrophages. The expression of CD36 mRNA were decreased in myricetin treated macrophages with ox-LDL incubation (\( P < 0.05 \)), while SR-A and SR-BI expression was not altered (Fig. 6a). Immunoblotting results showed that the protein level of CD36 was significantly reduced in myricetin treated macrophages (Fig. 6b).

Upon cholesterol loading, ABCA-1 mRNA and protein levels were not altered in vehicle and myricetin treated macrophages (Fig. 6a and 6b).

Discussion

The main purpose of this study was to evaluate the effect of myricetin on atherosclerotic development using \( \text{Ldlr}^{-/-} \) mice. Myricetin is a naturally occurring flavonoid and the anti-inflammation effect of myricetin has well been established [19, 20]. However, the efficacy of myricetin on atherogenesis and the mechanism remained elusive. The present study demonstrates that myricetin has an inhibitory effect on the development of atherosclerotic lesions in atherosclerosis-prone \( \text{Ldlr}^{-/-} \) mice, which could be related to suppression of cholesterol accumulation in macrophage foam cells. In macrophages, incubation with myricetin attenuated ox-LDL-induced cholesterol accumulation, and this effect may be involved in reduction of CD36-dependent ox-LDL uptake. Our findings strongly indicate that myricetin has a protective effect in maintenance of cholesterol homeostasis during the formation of foam cells in atherogenesis.

Myricetin naturally exists in many foods, especially in wine and grapes. Recent studies have demonstrated many health benefits of myricetin including antioxidative [21], anticarcinogenic [22], antiplatelet activities [10], cytoprotective effects [23], anti-obesity [16], improving glucose utilization [17] and plasma lipids profile [15]. In our study, myricetin treatment reduced body weight but not food intake, this anti-obesity effect is consistent with previous findings [16]. When \( \text{Ldlr}^{-/-} \) mice were fed an AsD for 8 weeks, plasma cholesterol reached as high as 1300 mg/dL. And, plasma cholesterol decreased significantly (~1000 mg/dL) after myricetin administration on
the same diet. The mechanism of lowering plasma cholesterol may be related to increasing the fatty acid oxidation mediating via peroxisome proliferator-activated receptor alpha (PPARα) activation which was reported in a previous study [15]. As high plasma triglyceride and cholesterol level increases the risk of atherosclerosis, the beneficial effect of myricetin for hypercholesterolemia and hypertriglyceridemia may caused profound reductions in atherosclerosis. The anti-atherogenesis effect of myricetin were shown in Oil red O staining of En face and the aortic root. Strikingly, histological analysis of aortic root lesions revealed significantly less macrophages in atherosclerotic plaques of Myr mice when compared with Control mice, but no difference in the amount of smooth muscle cells and collagen content. Taken together, myricetin may have a protective role in atherosclerosis, not only ameliorating plaque size, but also maintaining plaque stability.

Macrophages play a crucial role in atherogenesis [6], and uptake of modified LDL by macrophage and then transformation into foam cells contribute to development and progression of atherosclerosis. The lipid homeostasis
in macrophages depends on the balance of influx and efflux of lipid in which scavenger receptors (SRs) are critically involved [24–26]. At least two members of this family, CD36 and scavenger receptors class A (SR-A), mediate the internalization of ox-LDL by macrophages, leading to cholesterol ester accumulation and foam cell formation [27, 28]. In contrast, the efflux of intracellular cholesterol to high-density lipoprotein is mediated by reverse cholesterol transporters, including class B scavenger receptor type I (SR-BI) and ATP-binding cassette transporter A1 (ABCA1) [29–31]. Interestingly, the uptake of modified LDL was inhibited in myricetin-treated macrophages, which is consistent with downregulation of CD36 expression. In the present study, attenuation of CD36 by myricetin but not SR-A or SR-BI, contribute to decreased cholesterol accumulation in macrophages. Meanwhile, foam cell formation was decreased in myricetin-treated macrophages which can be partly attributed to myricetin effect on cholesterol esterification. Indeed, cholesterol ester formation was reduced in myricetin-treated macrophages upon ox-LDL loading, and cholesterol efflux was not affected. The mechanism of reduced cholesterol ester formation remains unclear.

The aim of this study was to investigate the anti-atherosclerotic activity of myricetin. The study was performed with Ldlr<sup>−/−</sup> mice which are characterized by accelerated development of atherosclerosis along with hypercholesterolemia. Despite the current widespread use of Ldlr<sup>−/−</sup> mice to mimic human atherosclerosis, obvious differences in murine genetic and metabolic profiles are observed [32, 33]. Hamsters display similar lipoprotein profiles and coronary atherosclerosis which could be an ideal animal for translational research of human atherosclerosis [34, 35]. Recently, Ldlr<sup>−/−</sup> hamster were successfully generated and serve as an ideal platform over other small animal models for basis and translational research of atherosclerosis [36]. Convincing evidence should be provided in Ldlr<sup>−/−</sup> hamster and we have plan to carry our this project. In summary, we have demonstrated that myricetin not only improved dyslipidemia, but also inhibit foam cell formation. These findings indicated that myricetin has therapeutic potentials in the prevention of atherogenic cardiovascular diseases.

**Conclusions**

In conclusion, our results show that myricetin regulates cholesterol uptake in macrophages through CD-36 pathway, resulting in an attenuation of atherosclerosis lesions. This findings suggested myricetin may have an important therapeutic function for atherosclerosis.

**Abbreviations**

ABCA1: ATP-binding cassette transporter A1; AsD: Atherogenic diet; Ldlr: Low-density-lipoprotein receptor; ox-LDL: Oxidized low-density lipoprotein; PPARα: Peroxisome proliferator-activated receptor alpha; SR-A: Scavenger receptors class A; SR-BI: Scavenger receptors class B; SRs: Scavenger receptors; TC: Total cholesterol; TG: Triglyceride and HDL-cholesterol; WAT: White adipose tissue

**Acknowledgements**

Not applicable

**Funding**

This study was supported by National Natural Science Foundation of China (grant number: NSFC 81600290).

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article or are available from the corresponding author on reasonable request.

**Authors’ contributions**

HYL designed the study; ZM, MYW, and JHX conducted the experiments; MYW did sample analysis and data analysis, ZM wrote the manuscript; HYL revised the paper. ZM and MYW contributed equally to this work. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

This study was approved by the ethics committee of ZhengZhou University.

**Consent for publication**

Not applicable

**Competing interests**

The authors declare they have no competing interests.
